Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancer

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. A blood biomarker for monitoring response to anti-EGFR therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Different expression of EZH2, BMI1 and Ki67 in low and high grade neuroendocrine tumors of the lung

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Triage May Improve Selection to Colonoscopy and Reduce the Number of Unnecessary Colonoscopies

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. eHealth-mind the gap

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
The epidermal growth factor receptor (EGFR) and angiogenesis are well established targets in anti-cancer therapy. Several targeted anti-cancer therapies are in clinical trials in pancreatic and gastroesophageal (GEJ) cancer. However, many patients do not respond to these targeted therapies and there is therefore an increasing need for biomarkers for selection of patients to these therapies. We investigated the expression of EGFR, vascular endothelial growth factor A (VEGF-A), and VEGF receptor 2 (VEGFR-2) in tumour tissue by immunohistochemistry, and soluble EGFR (sEGFR), soluble VEGFR-2 (sVEGFR-2), basic fibroblast growth factor (bFGF), placental growth factor (PlGF), plasminogen activator inhibitor 1 (PAI-1), and different forms of the urokinase plasminogen activator receptor (uPAR): uPAR (I), uPAR (I-III), and uPAR (I-III)+(II-III) in plasma by quantitative immunoassays in 14 patients with pancreatic and GEJ cancer. We found expression in tumour tissue and the plasma levels to be similar to those found in patients with other tumour types. No correlation was found between the blood levels of soluble receptors and the corresponding tumour tissue levels. We conclude that these markers are present in pancreatic and GEJ cancer patients, and could be investigated further as predictive biomarkers in such patients treated with EGFR or angiogenesis targeted therapies.
Original languageEnglish
JournalCancer biomarkers : section A of Disease markers
Volume7
Issue number3
Pages (from-to)141-51
Number of pages11
DOIs
Publication statusPublished - 1 Jan 2010

ID: 32249276